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The novel Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 is a potential factor for fatal illness
and a tremendous concern for global public health. The COVID-19 pandemic has entered a dangerous new
phase. In the context of drug discovery, the structurally-unique and chemically-diverse natural products
have been valuable sources for drug leads. In this review, we report for potential candidates derived from
natural sources with well-reported in vitro efficacy against SARS-CoV during the last decade.
Additionally, a library of 496 phenolic metabolites was subjected to a computer-aided virtual screening
against the active site of the recently reported SARS-CoV Main protease (Mpro). Analysis of
physicochemical properties of these natural products has been carried out and presented for all the
tested phenolic metabolites. Only three of the top candidates, viz. acetylglucopetunidin (31),
isoxanthohumol (32) and ellagic acid (33), which are widely available in many edible fruits, obey both
Lipinski's and Veber's rules of drug-likeness and thus possess high degrees of predicted bioavailability.
These natural products are suggested as potential drug candidates for the development of anti-SARS-
CoV-2 therapeutics in the near future.1. Introduction
Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV) is
rapidly re-evolving and causing a global outbreak named
“COVID-19” that is threatening hundreds of thousands of
people all over the world. Similar outbreaks with the rst wave
of SARS-CoV emerged in southern China in 2002. In 2012,
another coronavirus outbreak emerged in Jeddah, Saudi Arabia
and spread within and beyond the Middle East. A Middle Eastof Pharmacy, Nahda University, 62513
Pharmacy, Arab Academy for Science,
lexandria, Egypt
aculty of Pharmacy, Nahda University,
Pharmacy, Beni-Suef University, 62514
harmacy, Nahda University, 62513 Beni-
ical Sciences, University of the West of
Egypt
harmacy, Minia University, 61519 Minia,
; Tel: +2-86-2347759
harmacy, Deraya University, Universities
ia, Egypt
tion (ESI) available. See DOI:
9802respiratory syndrome caused by coronavirus (MERS-CoV) was
reported this time to be associated with severe pneumonia and
multi-organ failure.1 A timeline depicting the reported SARS-
CoV-2 outbreaks is shown in Fig. 1A. Etiologically, SARS-CoV
belongs to the genus Coronaviridae, a positive strand family.
The enveloped RNA viruses have a membrane comprising four
viral proteins i.e. spike glycoprotein (S), membrane glycoprotein
(M), nucleocapsid proteins (N) and an envelope protein (E)
(Fig. 1B). These proteins function during host cell entry and
viral morphogenesis and release S-glycoprotein on the surface
of the virus, which is responsible for virus attachment to a host
receptor named ACE-II.2
SARS-CoV genome is predominated by two open reading
frames that are connected by a ribosomal frameshi site, and
that encode two replicase proteins, viz. pp1a and pp1ab.3 pp1a
and pp1b produce viral functional proteins via proteolytic
process performed by the aid of two proteases i.e. papain-like
cysteine protease (PLpro) and chemotrypsin-like cysteine
protease (3CLpro). The latter is also called Main protease (Mpro),
which is vital to the viral replication and virulence.4
We aimed in this review to compile an updated knowledge
on the natural products with proven in vitro anti-SARS CoV re-
ported during the period from 2005 till the beginning of 2020.
We searched PubMed and Google Scholar for English language
articles published without start date restrictions up to April 15th
2020 with the keywords: “anti-SARS CoV”, “natural products as
Mpro, PLpro, ACE2-S-protein, helicase inhibitors”, “naturalThis journal is © The Royal Society of Chemistry 2020
Fig. 1 (A) Timeline of SARS-CoV outbreaks during the last two decades. (B) Coronavirus structure and its life cycle, illustrating themainmolecular
targets and their inhibitors.
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View Article Onlineproducts against SARS-CoV”. Cross-referencing and “related
articles” functions were used to expand the search criteria.
Searches were further supplemented with publicly available
information and reports from US Centers for Disease Control
and Prevention andWHOwebsites. Furthermore, we carried out
an in silico exploration of a library of phenolic natural products
(496 compounds) via a computer-aided virtual screening
against the active site of the SARS-CoVMain protease (Mpro) and
a drug-likeness computation of the compounds reported in this
review (75 compounds).This journal is © The Royal Society of Chemistry 20202. Anti-SARS CoV therapeutic drugs
2.1. Virus-based targets and their therapeutics
Many plant derived therapeutics exhibited an in vitro efficacy
against multiple SARS viral targets viz. viral entry into host cells,
viral processing (viral protease), viral replication (transcription
and translation), and viral release from infected cells (Fig. 1B).
SARS-CoV replicase gene has been revealed to encode
a number of enzymatic functions.5 These include Mpro (nsp5),
a papain-like protease (PLpro, nsp3), an RNA-dependent RNARSC Adv., 2020, 10, 19790–19802 | 19791
Fig. 2 Representative natural products with SARS CoV S-protein-ACE-II binding inhibitory action (in vitro) viz. anthraquinones (blue) and tannins
(brown).
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View Article Onlinepolymerase (RdRp, nsp12), and a helicase (HEL1, nsp13). Such
essential functional proteins have been selected as potential
targets for the development of new anti-SARS CoV therapeutics
during the last two decades. Both viral Mpro and PLpro cleave two
large replicase polyproteins, viz. pp1a and pp1ab, that are
encoded by the open reading frame 1a/b (ORF1a/b) to produce
a number of non-structural proteins (nsp 1–15) such as RNA-
dependent RNA polymerases (RdRp) and helicases that
initiate the viral replication process. Such proteases can be
considered key factors in the viral life cycle.6 Accordingly, their
in vitro and in vivo inhibition has exhibited anti-SARS CoV
potential (Fig. 1B).
Several small molecules inhibitors for these two enzymes
have been reported since 2002 (outlined in Fig. 1B), of which
both lopinavir and ritonavir showed a broad spectrum in vitro
Mpro inhibitory activity7 as well as clinical efficacy in patients
infected by COVID-19.8 Similarly, a number of specic and
selective inhibitors have been developed against PLpro, and two
of them with a common naphthalene benzamide scaffold are
under clinical trials now.9,10 Broad-spectrum RdRp and helicase
inhibitors like ribavirin and bananin, respectively have shown
some clinical efficacy against SARS-CoV and MERS-CoV.11,12 The
CoV small hydrophobic envelope protein (E-protein) was found
to contain cation-selective ion channels similar to the mouse
hepatitis virus (MHV) and human immunodeciency virus
(HIV). Inhibitors for such ion channels like hexamethylene
amiloride have a well-proven in vitro and in vivo anti-CoV
efficacy.132.2. Host-based targets and their therapeutics
ACE-II enzyme was found to be a functional and specic
receptor for the viral spike-glycoproteins (S-protein). Hence, its
antibodies were able to interfere with the viral entry to the host19792 | RSC Adv., 2020, 10, 19790–19802cells, and thus blocking viral replication.14 The spike glycopro-
teins (S1 and S2 subunits) were also reported to be potential
targets for neutralizing antibodies and oligosaccharide-specic
binding proteins (e.g. Griffithsin, a natural product derived
from the red algae Griffithsia), in addition to several small
molecules fusion inhibitors (S2 subunit inhibitors).15 Other
host proteases that could be targeted for drug development
include the endosomal cysteine protease i.e. cathepsins that
facilitate endosomal cell entry of CoV,16 and both the trans-
membrane protease serine 2 (TMPRSS2) and furin, that cleave
and activate spike proteins into the S1 and S2 subunits to
mediate the non-endosomal virus entry at the plasma
membrane.17 The broad-spectrum serine protease inhibitor
camostat possessed in vitro inhibitory activity toward cathep-
sins, furin and TMPRSS2 and signicant in vivo efficacy.
Moreover, viral entry via endocytosis was also found to be
inhibited by cardiotonic steroids such as ouabain and bufalin at
nanomolar concentrations18 (Fig. 1B).3. Anti-SARS CoV natural
therapeutics
3.1. Viral entry inhibitors
Natural therapeutic agents that target viral entry are considered
an important class of antiviral therapeutics because of their
potential to block the rst step of viral infection and hence,
preventing its propagation and ability to evolve and acquire
drug resistance. SARS-CoV virus entry is initiated when the
spike glycoprotein (S) efficiently bind with a metallopeptidase,
ACE-II on host cell.19
3.1.1. S-protein-ACE-II binding inhibitors. Several natural
products that target CoV S-protein to prevent its binding with
ACE-II, have been reported. In 2004, a group of ChineseThis journal is © The Royal Society of Chemistry 2020
Fig. 3 Representative natural products with SARS CoV Mpro in vitro inhibitory action viz. alkaloids (blue), coumarins (red), tannins (orange),
peptides (brown), terpenes (purple) and flavonoids (black).
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View Article Onlineresearchers screened their traditional herbal medicine (Tradi-
tional Chinese Medicine, TCM) for potential natural products
that can bind with S-protein. Their extensive virtual screening
followed by in vitro validation enabled them to identify
a number of phenolic compounds, among which tetra-O-galloyl-
b-D-glucose (1) (Fig. 2) was reported as a potent S-protein-ACE-II
binding inhibitor (IC50 4.5 mM).20 Three years later, another
Chinese research group screened a large number of medicinal
plants belonging to Polygonaceae family, i.e. Rheum officinaleThis journal is © The Royal Society of Chemistry 2020and Polygonum multiorum, for the possible discovery of anti-
CoV natural therapeutics. They found that emodin (2) and its
related anthraquinone derivative, i.e. rhein (3) signicantly
blocked the ACE-II and S-protein interaction in a dose-
dependent manner with IC50 of 1–10 mM (Fig. 2).21 Thereaer,
this class of compounds inspired the synthesis of an
anthraquinone-based derivative such as SSAA09E3 (4) (IC50 9.7
mM) (Fig. 2) which exhibited interesting pharmacodynamic and
pharmacokinetic properties and hence, it was selected to beRSC Adv., 2020, 10, 19790–19802 | 19793
Fig. 4 Representative natural products with SARS CoV PLpro in vitro inhibitory action viz. chalcones (blue), terpenes (Red), flavonoids (orange),
alkaloids (brown), coumarins (purple), and viral release inhibitors viz. flavonoid glycosides (black).
RSC Advances Review
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 2
7 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 6
/1
/2
02
0 
3:
09
:1
8 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Onlinefurther subjected for preclinical evaluation as a CoV entry
inhibitor.223.2. Inhibitors of viral replication
Being one of the most prominent molecular targets in COVID-
19, Mpro and PLpro inhibitors were selected for the develop-
ment of potential anti-SARS CoV therapeutics. Several small
molecules have been developed during and aer the rst and
second CoV spread waves. Among which, many edible plants-
derived natural products and their related synthetic deriva-
tives have offered a number of interesting potential inhibitors
with well-proven safety and efficacy.
3.2.1. Mpro inhibitors. Isatis indigotica was one of the rst
medicinal plants that have been reported to possess anti-SARS
CoV potential. A deeper investigation into its metabolites that19794 | RSC Adv., 2020, 10, 19790–19802could be attributable to the observed antiviral action led to the
characterization of several isatin-derived alkaloids indican (5)
and indigo (6) (Fig. 3) and other phenolic compounds with Mpro
in vitro inhibitory action.23 A year later, the isatin scaffold was
utilized for developing more potent semi-synthetic derivative (7)
that possessed Mpro inhibitory action at nanomolar concentra-
tions with IC50 of 0.37 mM (Fig. 3).24
The rapid development of computer-aided drug design
(CADD) used for the in silicomolecular modelling along with the
growing small molecules libraries derived by the aid of combi-
natorial chemistry have dramatically improved the drug
discovery and development process. During the last coronavirus
waves, such computer-based approaches have contributed to
nding a wide array of new and potent drug leads. Natural
product libraries and databases have also been utilized to ndThis journal is © The Royal Society of Chemistry 2020
Fig. 5 Pie charts indicating the reported anti-SARS CoV natural therapeutic classes (A & B), and their common viral targets (C). A bar chart
depicting activity range of the reported natural products illustrating phenolic compounds as being the most prominent class of compounds (D).
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View Article Onlinepotential anti-SARS CoV therapeutics. In 2004, shortly aer the
rst SARS-CoV spread, a number of polyphenolic metabolites of
which tannic acid (8), and theaavin-3,30-digallate (9) (Fig. 3)
were reported as potent viral Mpro inhibitors (IC50 3 and 9.5 mM,
respectively). These compounds were ltered out from a library
of phenolic compounds consisted of 720 compounds using an
in silico approach called structure-based virtual screening.25
Later on, a number of natural peptides i.e. tokaramide A (10)
(Fig. 3) derived from the marine organism Theonella mir-
abilis26,27 inspired another research group to develop a semi-
synthetic peptide derivative i.e. TG-0205221 (11) with
a nanomolar Mpro inhibition activity (IC50 0.6 mM), where they
exhibited a non-competitive inhibition through the formation
of covalent bonds with their binding sites (Fig. 3).28 Following
the screening of natural product databases, another research
group reported for hyperoside (quercetin-3-b-galactoside) (12)
as being a promising Mpro inhibitor with IC50 of 42.79 mM. They
also studied the structure–activity relationship of this avonoid
in comparison with a number of related derivatives and found
that a hydroxyl group at C-30 is an essential structural require-
ment for hyperoside competitive inhibitory action (Fig. 3).29
As part of the ongoing investigation of avonoids-based
antiviral candidates, Ryu and co-workers in 2010, reported theThis journal is © The Royal Society of Chemistry 2020Mpro inhibitory activity (IC50 20–200 mM) of some common
avonoids i.e. quercetin, apigenin and luteolin (13) and bio-
avonoids such as amentoavone (14), with the latter possess-
ing better in vitro inhibitory activity (IC50 8.3 mM). These
ndings revealed that larger polyhydroxylated compounds are
more preferred to develop potent Mpro noncompetitive inhibi-
tors (Fig. 3).30 Such interesting activity together with the
simplicity of avonoids-based inhibitors encouraged another
researcher group to develop potent inhibitors analogs such as
compound (15) based on the avonoids scaffold which were
subjected for a preclinical trial (Fig. 3).31 In 2013, eight phlor-
otannins, isolated from an edible brown algae Ecklonia cava,
namely eckol (16), dieckol, triphloretol A, dioxinodehydroeckol,
2-phloroeckol, 7-phloroeckol, fucodiphloroethol G and phlor-
ofucofuroeckol A, with the rst two compounds (Fig. 3) pos-
sessing the most potent SARS-CoV Mpro inhibitory activities
(IC50 8.8 and 2.7 mM, respectively).32 Epigallocatechin gallate
and gallocatechin gallate showed good Mpro inhibition activity
(IC50 73 and 47 mM, respectively) with their galloyl moiety at 3-
OH position required for the antiviral action.33
Herbacetin, rhoifolin and pectolinarin showed anti-SARS-
CoV Mpro action (IC50 33.17, 27.45 and 37.78 mM, respectively)
using a tryptophan-based uorescence method.34RSC Adv., 2020, 10, 19790–19802 | 19795
Fig. 6 Analysis of the physicochemical properties of anti-SARS CoV natural products displayed in terms of molecular weight (A), calculated log P
(B), HBD (C), HBA (D), number of rotatable bonds (E), and tPSA (F).
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View Article OnlineScutellarein, myricetin, quercetagetin, and robinetin were
reported in a Chinese patent to inhibit SARS Mpro activity in
a uorescent assay.2 The former two compounds also were
proved to inhibit the SARS-CoV helicase protein in vitro by
affecting the ATPase activity.35 High throughput screening of
natural product libraries led to the discovery of two interesting
Mpro competitive inhibitors i.e. betulinic acid (17) and savinin
(18) (IC50 8.2 and 9.1 mM, respectively). Both compounds were
able to bind the enzyme's active site constituting S1 and S2
subsites viamultiple hydrogen bonds with Asn 142, Gln 189 and19796 | RSC Adv., 2020, 10, 19790–19802Cys 145 amino acid residues. Thus, they could be promising
starting points for developing more potent derivatives, partic-
ularly, betulinic acid (17) (Fig. 3) which is abundant in many
edible and medicinal plants.36
Four quinone-methide triterpenes were reported to exhibit
Mpro inhibitory actions namely celastrol, pristimerin, tingenone
and iguesterin (IC50 10.3, 5.5, 9.9, and 2.6 mM, respectively),
which were isolated from the bark of Tripterygium regelii (F.
Celastraceae), a woody vine used in traditional ChineseThis journal is © The Royal Society of Chemistry 2020
Fig. 7 The compliance of the tested natural products with drug-likeness rules Lipinski's and Veber's rules (A & B, respectively). The relationship
between the IC50 and both tPSA and the number of rotatable bond (C & D, respectively). Distribution of the reported anti-SARS CoV natural
products depending on their scaffold's complexity (E).
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View Article Onlinemedicine in the treatment of inammatory and autoimmune
diseases.37
A coumarin compound named esculetin-4-carboxylic acid
ethyl ester (19) (Fig. 3), isolated from tropical marine sponge
Axinella corrugata, was reported to possess Mpro inhibitory
action with IC50 value of 46 mM.38 Isolinoleic acid (at a concen-
tration of 50 mM) possessed Mpro inhibitory potential as re-
ported in another Chinese patency.2This journal is © The Royal Society of Chemistry 20203.2.2. PLpro inhibitors. In vitro activity against CoV PLpro
was reported by a number of natural products such as gerany-
lated avonoids (Fig. 4), i.e. tomentin A (20), tomentin B,
tomentin C, tomentin D, tomentin E, 30-O-methyldiplacol, 40-O-
methyldiplacol, 30-O-methyldiplacone, 40-O-methyldiplacone,
mimulone, diplacone, and 6-geranyl-40,5,7-trihydroxy-30,50-
dimethoxyavanone, isolated from Paulownia tomentosa
fruits.39 Tanshinones isolated from Salvia miltiorrhiza,40 andRSC Adv., 2020, 10, 19790–19802 | 19797
Fig. 8 An outline of the employed virtual screening methodology that
comprised of (A) phenolic compounds library virtual screening via
molecular docking, (B) selection of the docking poses maintaining the
essential binding interactions and (C) selection of top phenolic hits
with the most acceptable drug-likeness properties.
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View Article Onlinediarylheptanoid hirsutenone derived from the stem bark of
Alnus japonica.41 Park and co-workers identied a number of
tanshinone derivatives as being potent PLpro inhibitors. One of
them (21) was found to be the most potent noncompetitive
inhibitor (IC50 0.8 mM), that was able to bind to the enzyme's
active site covalently. In parallel work, the same research group
characterized a diarylheptanoid derivative hirsutenone (22)
with an a,b-unsaturated carbonyl group that was also able to
form a covalent bond with a cysteine residue (Cys-145) in the
enzyme's active site leading to a signicant in vitro inhibition
(IC50 4.1 mM). They also reported a novel geranylated avonoid
derivative with a dihydro-2H-pyran moiety with promising
inhibitory activity (IC50 value of 5 mM).42
Recently, Park and his co-workers identied several poly-
hydroxylated chalcone derivatives, i.e. isobavachalcone (23), 4-
hydroxyderricin, xanthoangelol, xanthoangelol F, xanthoange-
lol D, xanthoangelol E, xanthoangelol B, xanthoangelol G and
xanthokeistal A, and coumarins from Angelica keiskei, i.e. psor-
alen, bergapten, xanthotoxin and isopimpinellin (Fig. 4), as
being potent competitive inhibitors of both Mpro and PLpro with
IC50 values ranging from 5.8 to 11.9 mM. Xanthoangelol E,
containing the perhydroxyl group, exhibited the most potent
Mpro and PLpro inhibitory activity with IC50 values of 11.4 and
1.2 mM, respectively.43 Another group of polyphenolic
compounds, were isolated from the medicinal plant Brousso-
netia papyrifera, of which a chalconoid derivative (24) showed
the best inhibitory potential against both Mpro and PLpro (IC50
27.9 and 112.9 mM, respectively).44 Tryptanthrin (25) isolated19798 | RSC Adv., 2020, 10, 19790–19802from Strobilanthes cusia leaf inhibited the cleavage activity of
PLpro and the post-entry stage of viral replication with IC50 of
1.52 mM.45 Six cinnamic amides i.e. N-trans-caffeoyltyramine, N-
trans-coumaroyltyramine, N-trans-feruloyltyramine, terrestria-
mide and N-trans-feruloyloctopamine, isolated from Tribulus
terrestris fruits, showed signicant PLpro inhibition (IC50 values
ranging from 15.8 to 70.1 mM). The latter compound possessed
the most potent inhibition with IC50 of 15.8 mM.46 Six phenolic
compounds with good PLpro inhibitory actions (IC50 ranging
between 4.2 and 38.4 mM), namely bavachinin, neo-
bavaisoavone, 40-O-methylbavachalcone, corylifol A, iso-
bavachalcone and psoralidin (26) were isolated from Psoralea
corylifolia seeds. The latter two compounds showed the most
potent actions with IC50 values of 7.3 and 4.2 mM, respectively.47
The inhibitory potential of ten polyphenols derived from
Broussonetia papyrifera roots, i.e. broussochalcone A, brousso-
chalcone B, 4-hydroxyisolonchocarpin, papyriavonol A (27), 3'-
(3-methylbut-2-enyl)-30,4,7-trihydroxyavane, kazinol A, kazinol
B, broussoavan A, kazinol F and kazinol J, were tested against
the two SARS CoV proteases with a more potent inhibition
recorded against PLpro than that of 3CL
pro. The most potent
PLpro inhibition was exhibited by the prenylated avone deriv-
ative viz. papyriavonol A (27) with IC50 value of 3.7 mM,
exceeding the inhibitory potential of non-prenylated avone
derivatives viz. quercetin and kaempferol (IC50 8.6 and 16.3 mM,
respectively). This signied the crucial role of the prenyl group
in forming stronger hydrophobic interactions with the enzyme
as well as the increase in the hydroxylation in the avone
backbone.483.3. Viral release inhibitors
Several kaempferol derivatives (Fig. 4) were reported to block
the 3a channel of Coronavirus, which are formed by the ORF 3a-
coded proteins, thus counteracting the viral production and
release from the host cells. This gives the body a chance to
adjust its immune system to counteract the viral attack.
Kaempferol glycosides were proved to possess more potent
inhibitory effect than kaempferol and this pointed out to the
signicance of sugar residues for the antiviral activity. Juglanin
(kaempferol-3-O-a-L-arabinofuranoside) (28) was the most
effective glycoside with an IC50 value of 2.3 mM. Other kaemp-
ferol glycosides i.e. tiliroside (kaempferol-3-O-(6-p-coumaroyl)-
glucoside) (29) and afzelin (kaempferol-3-O-a-L-rhamnoside)
(30) were less potent than juglanin (28) but showed similar
activity to that of emodin (2).494. Analysis of drug-likeness
properties
The druggability of any molecule is determined depending on
its pharmacokinetic properties as well as its excellent pharma-
codynamics. Calculating the physicochemical properties (e.g.
log P and molecular weight) of a bioactive compound can
predict its possible pharmacokinetics (e.g. absorption and
bioavailability). Lipinski's rule of ve considers a given bioac-
tive compound as a drug candidate if it possess the followingThis journal is © The Royal Society of Chemistry 2020
Fig. 9 The main pharmacophore of the top three hits (A), along with their binding modes inside SARS CoV Mpro active sites (B & C). The binding
modes of the hydrolysis metabolites derived from compounds 31 and 32 (D).
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View Article Onlinephysicochemical parameters i.e. log P # 5, molecular weight #
500, hydrogen bond donor [HBD] # 5, and hydrogen bond
acceptor [HBA] # 10. Despite, 90% of orally active drugs that
have reached phase 2 clinical status50 follow these parameters
range, however, meeting the rule of ve does not guarantee that
a molecule is a drug-like.51 Drug's cellular permeability and in
turn its distribution and excretion are associated with its
topological polar surface area (tPSA) and molecular exibility
(i.e. the number of rotatable bonds). Hence, bioactive molecules
with tPSA of 140 A or less and rotatable bonds of ten or fewerThis journal is © The Royal Society of Chemistry 2020(i.e. Veber's oral bioavailability) can be considered as potential
drug candidates.51
In this review, the 74 anti-CoV natural products (Table S1,
ESI†) were found to belong to four classes of compounds viz.
phenolics, terpenoids, alkaloids and peptides, where phenolics
were the most prominent compounds of which avonoids were
the major class (72%) (Fig. 5). The majority of compounds were
found targeting Mpro and PLpro (55% and 26%, respectively,
Fig. 5) indicating that they are the most susceptible targets
towards natural products, particularly the phenolics. The anti-
viral activity of these compounds possessed activity rangingRSC Adv., 2020, 10, 19790–19802 | 19799
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View Article Onlinefrom potent to moderate (IC50 ranging from 0.0025 to 90 mM,
average IC50 20.13 mM), where phenolics were also the most
active ones (Fig. 5). The physicochemical characters, viz.
molecular weight, log P, HBD, HBA, tPSA and rotatable bonds,
of the 74 anti-SARS CoV were calculated using LigandScout 4.3
(Vienna, Austria) and projected onto a drug-likeness cut-off.52
Regarding the drug-likeness properties, 76% of the reviewed
molecules followed Lipinski's and Veber's rules (Fig. 7), indi-
cating the promising potential of natural products to serve as
drug candidates against the newly emerged anti-SARS CoV. The
molecular weights of the 74 compounds distributed between
248.24 and 1701.2 Da (average of 138.248 Da), andmost of them
were between 200 and 400 Da (Fig. 6). Both tannic acid and b-
aescin were the largest molecules. However, they showed potent
anti-SARS CoV (IC50 3 and 6 mM, respectively). The log P of the
compounds under study followed a normal distribution with
the major was around 2, and 79% of the compounds were of
favourable log P values (#5) (Fig. 6). Regarding HBD and HBA
parameters (average of 3 and 4, respectively, Fig. 6), they showed
a distribution pattern similar to that of log P (Fig. 6) with more
than 80% of compounds were of acceptable numbers. Addi-
tionally, 74% of compounds can demonstrate good oral
bioavailability (Fig. 6). Being the most predominant and active
compounds, phenolic's tPSA and to some extent of exibility
(number of rotatable bonds) which are interestingly linked to
their activity. The compounds with higher tPSA and number of
rotatable bonds (i.e. exible) were found to exhibit higher IC50
values (Fig. 7). Such observation was also found in the peptides
class, as they were among the most active compounds (IC50
0.0025 to 6.8 mM), and also have high tPSA (>140 A) and high
exibility (rotatable bonds 12 to 27). Natural products are not
always available to supply the drug industry due to their limited
natural occurrence for some ecological considerations.
Accordingly, combinatorial chemistry can aid in providing an
alternative source for the natural product itself or its analogs. In
this context, we examined the complexity and the synthetic
accessibility of our reviewed natural products. As illustrated in
Fig. 7, most of the compounds (>85%) got a score ranging from
2 to 5, indicating that they or their analogs could be synthesized
if the natural product itself cannot be readily accessible.5. In silico analysis of potential anti
SARS-CoV 2 agents
Virtual screening (VS) proved to be a helpful tool for drug hit/
lead identication. Many studies have recently employed in
silico exploration of large sets of natural products with the aid of
online databases in attempt to discover new hits against
potential molecular targets. Among which, a study by ul
Qamar M. T. reported for structural insights into anti-viral
phytochemicals/traditional Chinese medicinal compounds
with in silico screening of 32 297 natural products for their
SARS-CoV-2 3CLpro inhibitory action.53 As shown in our in silico
analysis, phenolic derivatives were the most prominent and
active compounds against previous CoVs (Fig. 5). Thus, we
subjected a library of phenolic metabolites,54 to a computer-19800 | RSC Adv., 2020, 10, 19790–19802aided virtual screening against the active site of the recently
reported COVID-19 Mpro (PDB code: 5R7Z) based on high-
throughput exible docking technique for the sake of nding
possible candidate acting as inhibitors for the newly emerged
SARS-CoV2. Thirty four compounds were ranked by highest
energy score and the poses that maintained the essential
interactions. Twelve compounds were retrieved as the top-hits
that t into the Mpro target pocket (Table S2, ESI†). Only three
of these top candidates obey both Lipinski's and Veber's rules of
drug-likeness (Fig. 8 and 9). The structure–activity relationship
analyses of the nal top-hits presented in Fig. 9(A) revealed that
they shared convergent interactions with the active site's amino
acid residues that are comparable with the previous CoV-main
proteases inhibitors. All top hits exhibited hydrogen bonding
interaction with Thr 190 via the hydroxyl phenolic group and
the carbonyl oxygen of Thr 190 residue. Additional hydrogen
bonding interactions were found to exist between ellagic acid
(33) and Met-165 or isoxanthohumol (32) and Cys-145.
Regarding van der Waal interactions, all the hits showed
interaction with Gln-189, which is assumed to be essential for
the activity (Fig. 9). Additionally, the presence of Gln-191, Glu-
166 and Cys-145 with some top-hits to form the hydrophobic
subsite in other CoV Mpro which may create an extra van der
Waal interactions. These essential interactions were found to be
missing in low-scoring compounds. The selected hits with drug-
like properties are well reported to be abundant in many edible
fruits such as raspberry and pomegranate. Hence, they are
readily available for the in vitro investigation to validate them as
potential anti-SARS CoV2 drug leads (Fig. 9). Regarding the
possibility of the metabolic unstability of acetylglucopetunidin
(31) and (2S)-isoxanthohumol (32), both compounds show the
presence of acetylester or methoxy groups that could be easily
hydrolyzed inside the human body. Accordingly, we redocked
their respective metabolites (34 & 35) to explore their inhibitory
potential. Both metabolites were found to reserve the same
hydrophobic and hydrogen bond interactions with His-41 and
Gln-189 amino acid residues, respectively however, they gained
an additional hydrogen bond interaction with Gln-189. More-
over, both metabolites bind with Cys-44 and Cys-145 via two
hydrogen bond donors with binding affinity of
7.147 kcal mol1. The metabolite of (2S)-isoxanthohumol (35)
was found to bind with the same three amino acid residues i.e.
Gln-189, Thr-190, and Glu-166, with a binding affinity of
6.021 kcal mol1, which was comparable to its parent
compound (32), however, an extra hydrogen bond donor with
Leu 141 was recorded (Fig. 9(D)).
6. Concluding remarks
The rapid identication of effective therapeutic interventions
against COVID-19 is a major challenging issue nowadays.
Taking into consideration that the development of new
synthetic drugs is a time-consuming process, so repurposing
the already known medications is the most convenient choice
under the current situation. Hence, natural products can
provide a valuable source for the rapid drug discovey of effective
as well as safe anti-SARS CoV therapeutics. As has beenThis journal is © The Royal Society of Chemistry 2020
Review RSC Advances
O
pe
n 
A
cc
es
s 
A
rt
ic
le
. P
ub
lis
he
d 
on
 2
7 
M
ay
 2
02
0.
 D
ow
nl
oa
de
d 
on
 6
/1
/2
02
0 
3:
09
:1
8 
PM
. 
 T
hi
s 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
C
om
m
on
s 
A
ttr
ib
ut
io
n-
N
on
C
om
m
er
ci
al
 3
.0
 U
np
or
te
d 
L
ic
en
ce
.
View Article Onlineillustrated in the current review, and other recently published
reviews, a wide array of chemically-diverse natural products
have proven to be excellent candidates as anti-SARS CoV, among
which phenolic derivatives, viz. avonoids were the most re-
ported active agents, due to their promising pharmacokinetic
proles.55
Being the most susceptible targets in CoV, both Mpro and
PLpro of SARS-CoV in addition to a number of host-based
proteases viz. cathepsins and furin, can be utilized for the
sake of developing broad-spectrum anti-SARS CoV therapeutic
agents that target multiple viral and non-viral proteins. Some
phenolics such as tannins and avonoids have exhibited
a broad-spectrum activity not only against SARS-CoV but also
other viruses56 Based on our ndings, tPSA and molecular
exibility are the most essential descriptors that should be
taken into consideration for selecting active and bioavailable
phenolic compounds. The reported IC50 values of SARS natural
products-inhibitors were mostly recorded in a micromolar
range. However, more potent synthetic or semi-synthetic
derivatives can be developed from the current scaffolds as
they showed low to moderate molecular complexity. With the
tremendous ongoing efforts to develop broad-spectrum anti-
viral therapeutics to combat coronaviruses and stop the rapid
spread of COVID-19 worldwide, we hope that the current
outbreak to settle down in a few months, as has been witnessed
previously with SARS and MERS pandemics.
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